{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:59:41Z","timestamp":1789664381572,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T00:00:00Z","timestamp":1608681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jns.2020.117277","type":"journal-article","created":{"date-parts":[[2020,12,20]],"date-time":"2020-12-20T10:10:37Z","timestamp":1608459037000},"page":"117277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study"],"prefix":"10.1016","volume":"421","author":[{"given":"Amy","family":"Bullock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inder","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Silber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Kanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jns.2020.117277_bb0005","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1523\/JNEUROSCI.3908-07.2008","article-title":"Differential tonic GABA conductances in striatal medium spiny neurons","volume":"28","author":"Ade","year":"2008","journal-title":"J. Neurosci."},{"issue":"10","key":"10.1016\/j.jns.2020.117277_bb0010","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/0166-2236(89)90074-X","article-title":"The functional anatomy of basal ganglia disorders","volume":"12","author":"Albin","year":"1989","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.jns.2020.117277_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108333","article-title":"Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator","volume":"181","author":"Althaus","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jns.2020.117277_bb0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eplepsyres.2015.01.001","article-title":"Progress report on new antiepileptic drugs: a summary of the twelfth EILAT conference (EILAT XII)","volume":"111","author":"Bialer","year":"2015","journal-title":"Epilepsy Res."},{"issue":"1","key":"10.1016\/j.jns.2020.117277_bb0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neuron.2011.12.012","article-title":"Extrasynaptic GABAA receptors: their function in the CNS and implications for disease","volume":"73","author":"Brickley","year":"2012","journal-title":"Neuron."},{"issue":"4","key":"10.1016\/j.jns.2020.117277_bb0030","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1017\/S0317167100017674","article-title":"Role of midazolam in parkinsonian tremors: to use or not to use","volume":"40","author":"Chowdhury","year":"2013","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.jns.2020.117277_bb0035","first-page":"2531812","article-title":"Can a positive allosteric modulation of GABAergic receptors improve motor symptoms in patients with Parkinson\u2019s disease? The potential role of zolpidem in the treatment of Parkinson\u2019s disease","volume":"2016","author":"Daniele","year":"2016","journal-title":"Parkinsons Dis."},{"issue":"19","key":"10.1016\/j.jns.2020.117277_bb0040","doi-asserted-by":"crossref","first-page":"5362","DOI":"10.1523\/JNEUROSCI.3634-15.2016","article-title":"The cerebral network of Parkinson\u2019s tremor: an effective connectivity fMRI study","volume":"36","author":"Dirkx","year":"2016","journal-title":"J. Neurosci."},{"issue":"8","key":"10.1016\/j.jns.2020.117277_bb0045","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"Et al; Movement Disorder Society evidence-based medicine company. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.jns.2020.117277_bb0050","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/jmri.25865","article-title":"Inhibitory motor dysfunction in Parkinson\u2019s disease subtypes","volume":"47","author":"Gong","year":"2017","journal-title":"J. Magn. Reson. Imaging"},{"issue":"1\u20132","key":"10.1016\/j.jns.2020.117277_bb0055","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0022-510X(90)90023-G","article-title":"Changes in benzodiazepine and acetylcholine receptors in the globus pallidus in Parkinson\u2019s disease","volume":"100","author":"Griffiths","year":"1990","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.jns.2020.117277_bb0060","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/mds.27224","article-title":"The cerebral basis of parkinsonian tremor: a network perspective","volume":"33","author":"Helmich","year":"2018","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.jns.2020.117277_bb0065","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40262-019-00801-0","article-title":"SAGE-217, a novel GABAA receptor positive allosteric modulator: clinical pharmacology and tolerability in randomized phase I dose-finding studies","volume":"59","author":"Hoffmann","year":"2020","journal-title":"Clin. Pharmacokinet."},{"issue":"2\u20133","key":"10.1016\/j.jns.2020.117277_bb0070","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0301-0082(95)80011-V","article-title":"The role of the cerebello-thalamo-cortical pathway in skilled movement","volume":"46","author":"Horne","year":"1995","journal-title":"Prog. Neurobiol."},{"issue":"2","key":"10.1016\/j.jns.2020.117277_bb0075","first-page":"219","article-title":"GABA signalling: therapeutic targets for epilepsy, Parkinson\u2019s disease and Huntington\u2019s disease","volume":"5","author":"Kleppner","year":"2001","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.jns.2020.117277_bb0080","first-page":"3","article-title":"The impact of tonic GABAA receptor-mediated inhibition on neuronal excitability varies across brain region and cell type","volume":"8","author":"Lee","year":"2014","journal-title":"Front. Neural. Circ."},{"issue":"12","key":"10.1016\/j.jns.2020.117277_bb0085","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3109\/00207454.2013.812085","article-title":"Rasagiline treatment effects on parkinsonian tremor","volume":"123","author":"Lew","year":"2013","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.jns.2020.117277_bb0090","first-page":"186","article-title":"Distinct roles of synaptic and extrasynaptic GABAA receptors in striatal inhibition dynamics","volume":"7","author":"Luo","year":"2013","journal-title":"Front. Neural. Circ."},{"issue":"4","key":"10.1016\/j.jns.2020.117277_bb0095","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/00002512-200016040-00003","article-title":"Tremor-predominant Parkinson\u2019s disease. Approaches to treatment","volume":"16","author":"Marjama-Lyons","year":"2000","journal-title":"Drugs Aging"},{"issue":"8","key":"10.1016\/j.jns.2020.117277_bb0100","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1021\/acs.jmedchem.5b00032","article-title":"Neuroactive steroids. 1. Positive allosteric modulators of the (\u03b3-aminobutyric acid)A receptor: structure\u2013activity relationships of heterocyclic substitution at C-21","volume":"58","author":"Martinez Botella","year":"2015","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.jns.2020.117277_bb0105","doi-asserted-by":"crossref","first-page":"7810","DOI":"10.1021\/acs.jmedchem.7b00846","article-title":"Neuroactive steroids. 2. 3\u03b1-Hydroxy-3\u03b2-methyl-21-(4-cyano 1H pyrazol-1\u2032-yl)-19-nor-5\u03b2-pregnan-20-one (SAGE-217): a clinical next generation neuroactive steroid positive allosteric modulator of the (\u03b3-aminobutyric acid)A receptor","volume":"60","author":"Martinez Botella","year":"2017","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.jns.2020.117277_bb0110","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1254\/jjp.48.331","article-title":"GABAA receptor but not muscarinic receptor density was decreased in the brain of patients with Parkinson\u2019s disease","volume":"48","author":"Nishino","year":"1988","journal-title":"Jpn. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.jns.2020.117277_bb0115","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/mds.26712","article-title":"Unmasking levodopa resistance in Parkinson\u2019s disease","volume":"31","author":"Nonnekes","year":"2016","journal-title":"Mov. Disord."},{"issue":"Suppl. 7","key":"10.1016\/j.jns.2020.117277_bb0120","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1002\/mds.10579","article-title":"Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?","volume":"18","author":"Pirker","year":"2003","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2020.117277_bb0125","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"6","key":"10.1016\/j.jns.2020.117277_bb0130","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/jnnp.72.6.713","article-title":"Pramipexole in patients with Parkinson\u2019s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study","volume":"72","author":"Pogarell","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.jns.2020.117277_bb0135","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/mds.27438","article-title":"Neurobiology of placebo effect in Parkinson\u2019s disease: what we have learned and where we are going","volume":"33","author":"Quattrone","year":"2018","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.jns.2020.117277_bb0140","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.tips.2016.04.003","article-title":"Clinical potential of neurosteroids for CNS disorders","volume":"37","author":"Reddy","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.jns.2020.117277_bb0145","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.mcna.2018.10.014","article-title":"Parkinson\u2019s disease","volume":"103","author":"Reich","year":"2019","journal-title":"Med. Clin. N. Am."},{"issue":"3","key":"10.1016\/j.jns.2020.117277_bb0155","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0168-0102(85)90010-0","article-title":"Synaptic organization of the cerebello-thalamo-cerebral pathway in the cat. II. Input-output organization of single thalamocortical neurons in the ventrolateral thalamus","volume":"2","author":"Shinoda","year":"1985","journal-title":"Neurosci. Res."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X20306134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X20306134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:52:22Z","timestamp":1758383542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X20306134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":30,"alternative-id":["S0022510X20306134"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2020.117277","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2020.117277","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117277"}}